Table 1 Characteristics of the study population, overall and by use of a statin. Mean (SD) if not otherwise indicated

Age (years)

83.3 (7.3)

85.7 (7.5)

81.0 (6.4)

−4.7 (−6.8 to − 2.6)

Female, n (%)

118 (67.8)

70 (80.5)

48 (55.2)

p < 0.01^b

BMI (kg/m²)

25.2 (5.6)^c

24.2 (5.4)

26.3 (5.6)

2.1 (0.4 to 3.8)

CIRS (0-56)

16.7 (4.3)

16.3 (4.3)

17.1 (4.2)

0.9 (−0.4 to 2.1)

FIM (18-126)

111.1 (10.8)

110.6 (10.4)

111.7 (11.1)

1.1 (−2.1 to 4.4)

CDR (0-18)

2.3 (3.3)

2.5 (3.3)

2.2 (3.4)

−0.3 (−1.3 to 0.7)

Grip strength (kg)

18.5 (8.1)

15.7 (6.8)

21.4 (8.3)

5.7 (3.4 to 8.0)

Grip strength indicating sarcopenia ^d, n (%)

105 (60)

61 (70)

44 (51)

p = 0.01^b

SPPB (0-12)

4.6 (3.1)

4.4 (3.0)

4.8 (3.2)

0.4 (−0.6 to 1.3)

SPPB ≤8, n (%)

149 (86)

74 (85)

75 (86)

p = 0.8^b

Gait speed (m/s)

0.62 (0.20)^e

0.59 (0.21)

0.64 (0.19)

0.06 (−0.01 to 0.11)

Gait speed ≤0.8 m/s, n (%)

128 (79)^e

68 (83)

60 (75)

p = 0.2^b

SPPB subscore balance (0-4)

1.6 (1.3)

1.6 (1.3)

1.7 (1.4)

0.1 (−0.3 to 0.5)

SPPB subscore chair stand (0-4)

0.8 (1.2)

0.8 (1.2)

0.8 (1.2)

0.0 (−0.3 to 0.4)

n (% of 87) using statin as secondary prevention

64 (74)